

Country

Name (Print/Type)

Signature

Mark J. Hyman

Please type a plus sign (+) inside this box ————

PTO/SB/05 (03-01)
Approved for use through 10/31/2002. OMB 0697 at
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it displays a valid OMB control

Fay

Date

46,789

March 7, 2002

Registration No. (Attorney/Agent)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. LITH ITY Attorney Docket PTZ29C1 PATENT APPLICATION First Inventor Rosen et al. TRANSMITTAL Title Nucleic Acids, Proteins, and Antibodies Express Mail Label (Only for new nonprovisional applications under 37 CFR 1.53(b)) Box Patent Application APPLICATION ELEMENTS ADDRESS TO: Commissioner for Patents See MPEP chapter 600 concerning utility patent application contents. Washington, DC 20231 X Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) (Submit an original, and a duplicate for fee processing) Applicant claims small entity status. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) a. X Computer Readable Form (CRF) X Specification (Total Pages 397 (preferred arrange nent set forth below) b. Specification Sequence Listing on: Descriptive title of the invention
 Cross Reference to Related Applicat i. X CD-ROM or CD-R (2 copies); or Statement Regarding Fed sponsored R & D
 Reference to sequence listing, a table, c. X Statements verifying identity of above copies or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention ACCOMPANYING APPLICATIONS PARTS Brief Description of the Drawings (if filed) Assignment Papers (cover sheet & document(s)) Detailed Description - Claim(s) 37 CFR 3.73(b) Statement X Associate Power of Attorney 10 - Abstract of the Disclosure (when there is an assignee) (Total Sheets Drawing(s) (35 U.S.C. 113) 11 English Translation Document (if applicable) Information Disclosure Copies of IDS 5 Oath or Declaration [Total Pages 12 Citations Statement (IDS)/PTO-1449 Newly executed (original or copy) 13. Preliminary Amendment b. X Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed) Return Receipt Postcard (MPEP 503) 14. (Should be specifically itemized) DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior applic 15 Certified Copy of Priority Document(s) (if foreign priority is claimed) Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). 16. see 37 CFR 1.63(d)(2) and 1.33(b). Applicant must attach form PTO/SB/35 or its equivalent. X Other: 1. Statement Under 37 C.F.R. § 1.821 17 2. Transmittal and Submission Under 37 6. X Application Data Sheet. See 37 CFR 1.76 (7 pages) C.F.R. §§ 1.824 and 1.52(e) 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76 X Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09/764,889 Clow, L. 1631 Prior application information: Examiner Group / Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by 19. CORRESPONDENCE ADDRESS Customer Number or Bar Code Correspondence address 22195 х Lahel helow Name Address Zip City State Code

Telephone

Complete (if applicable)

Telephone (240) 314-1224

March 7, 2002

Page 1997 | Approved for use through 10/31/2002. DOB 9651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it disaylars avail doll to control

Complete if Known **FEE TRANSMITTAL** Application Number Not Yet Assigned for FY 2002 Filing Date Herewith First Named Inventor Rosen et al Patent fees are subject to annual revision Examiner Name Not Yet Assigned Application claims small entity status. See 37 CFR 1.27 Not Yet Assigned Group Art Unit TOTAL AMOUNT OF PAYMENT (\$) 896.00 Attorney Docket No. PTZ29C1 METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) 3. ADDITIONAL FEES χ Deposit Account Large Entity Small Entity Deposit 08-3425 Fee Fee Fee (\$) Code (\$) Fee Description Number Fee Paid 105 130 205 65 Surcharge - late filing fee or oath Account Human Genome Sciences, Inc. Surcharge - late provisional filing fee or cover 50 227 25 The Commissioner is hereby authorized to: (check all that apply) X Charge fee(s) indicated below X Credit any overpayments 139 130 139 130 Non-English specification Charge any additional fee(s) during the pendency of this x 2,520 147 2,520 For filing a request for ex parte reexamination Requesting publication of SIR prior to 920* 112 920* 112 Charge fee(s) indicated below, except for the filing fee Evaminer action Requesting publication of SIR after to the above-identified deposit account 113 1,840 113 1 840* Examiner action FEE CALCULATION 115 110 215 55 Extension for reply within first month 1. BASIC FILING FEE 116 400 216 Extension for reply within second month Large Entity Small Entity 117 920 217 Extension for reply within third month Foo F Extension for reply within fourth month Fee Description 118 1.440 218 720 Code Code (\$) (\$) Fee Paid 370 Utility filing fee 128 1,960 228 980 Extension for reply within fifth month 101 740 201 740.00 106 330 206 165 Design filing fee 119 320 219 Notice of Appeal 107 510 207 255 Plant filing fee 120 320 220 Filing a brief in support of an appeal 108 740 208 370 Reissue filing fee 121 280 221 140 Request for oral hearing 160 214 80 Provisional filing fee 138 1,510 138 1,510 Petition to institute a public use proceeding 140 110 240 55 Petition to revive - unavoidable SUBTOTAL (1) (\$) 740.00 Petition to revive - unintentional 141 1 280 241 640 2. FXTRA CLAIM FEES FOR UTILITY AND REISSUE 142 1 280 242 640 Utility issue fee (or reissue) 143 243 230 Design issue fee Claims below Total Claims 24 -20** = 144 244 4 1 72.00 620 310 Plant issue fee 18.00 Independent 4 -3** = 122 122 130 Petitions to the Commissioner 123 50 123 Processing fee under 37 CFR 1.17(a) Multiple Dependent Submission of Information Disclosure Stmt 126 180 126 180 Large Entity Small Entity Recording each patent assignment per Fee Description 591 40 591 40 Code (5) orocerty (times number of properties) Filing a submission after final rejection (37 CFR 1.129(a)) 103 203 9 Claims in excess of 20 18 146 740 246 102 84 202 42 Independent claims in excess of 3 For each additional invention to be examined (37CFR 1 129(b)) 140 740 240 370 204 140 Multiple dependent claim, if not paid 104 280 109 84 209 ** Reissue independent claims 179 279 Request for Continued Examination (RCE) over original patent Request for expedited examination of a design application 169 900 169 210 " Reissue claims in excess of 20 110 18 and over original patent Other fee (specify) SUBTOTAL (2) (S) SUBTOTAL (3) (S) *Reduced by Basic Filing Fee Paid 156.00 **or number previously paid, if greater; For Reissues, see above

Registration No. (Attorney/Agent) 46,789

SUBMITTED BY

Signature

Name (Print/Type) Mark J. Hyman

VIA HAND DELIVERY MARCH 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PTZ29C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies

TRANSMITTAL AND SUBMISSION UNDER 37 C.F.R. §§ 1.824 AND 1.52(e)

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.821(e) and 1.824, Applicants submit herewith a Sequence Listing satisfying the computer readable format requirements on a compact disc (CD-R) labeled "CRF," Applicants submit concurrently herewith a Statement Under 37 C.F.R. § 1.821.

Additionally, in accordance with 37 C.F.R. §§ 1.52(e), 1.821, and 1.823, Applicants submit herewith a Sequence Listing as an electronic document on two identical compact discs (CD-R). Applicants certify under 37 C.F.R. § 1.52(e)(4) that these two compact discs, labeled "Copy 1" and "Copy 2," are identical. These compact discs, formatted for an IBM-PC machine and compatible with the MS-Windows operating system, each contain the file "PTZ29C1 seqList.txt" (43,108 bytes in size, created March 6, 2002).

Respectfully submitted,

Dated: March 7, 2002

Attorney for Applicants

Reg. No. 46,789

Human Genome Sciences, Inc. 9410 Key West Avenue Rockville, MD 20850 Telephone: (240) 314-1224

Enclosures